Zydus Lifesciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Zydus Lifesciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹36 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 92% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹67 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 91% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹90Over the last 3 years, every ₹100 of reported profit came with ₹90 of operating cash.
Lower than 58% of Healthcare companies in India.
Self-Funding Ratio
2.3×Over the last 3 years its own operating cash covered its investment spending (capex) 2.3 times.
Higher than 73% of Healthcare companies in India.
Cash Locked Ratio
₹28For every ₹100 of sales, ₹28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 58% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹31Sales grew 58% in 3 years; of every extra ₹100 of sales, ₹31 became extra profit.
Higher than 78% of Healthcare companies in India.
Asset Productivity Ratio
+58% / +103%In 3 years sales changed by +58% while total assets changed by +103%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 81% of Healthcare companies in India.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 70% of Healthcare companies in India.
Tangible Assets Ratio
67%Of every ₹100 the company owns, ₹67 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 91% of Healthcare companies in India.
Tangible Net Worth Ratio
36%Of every ₹100 of net worth, ₹36 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 92% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Zydus Lifesciences Limited owes ₹0.44 for every ₹1 it owns. Net profit rose 11% in the year to Mar 2026, and grew 37% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
25.2Investors pay ₹25.2 for every ₹1 of Zydus Lifesciences Limited's yearly profit, lower than 72% of Healthcare companies in India.
P/B ratio
4.16The share price is 4.16 times Zydus Lifesciences Limited's book value per share, lower than 58% of Healthcare companies in India.
Market cap
₹112,658 CrThe total market value of all of Zydus Lifesciences Limited's shares at today's price (share price × number of shares), larger than 98% of Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹27,111 CrWhat Zydus Lifesciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹271.79Net worth divided by the number of shares. The share price of ₹1,129 is 4.2 times this, which is the P/B above.
Return on equity (ROE)
16.6%Zydus Lifesciences Limited earned 16.6% on its shareholders' money over the last year, higher than 64% of Healthcare companies in India.
Owes vs Owns
0.44×Zydus Lifesciences Limited owes ₹0.44 for every ₹1 it owns (low), higher than 67% of Healthcare companies in India.
Dividend yield
0.09%Zydus Lifesciences Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Revenue growth
+18%Revenue rose 18% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit growth
+11%Net profit rose 11% in the year to Mar 2026, and grew 37% a year on average over 3 years.
Profit margin
18.9%Zydus Lifesciences Limited keeps ₹19 of every ₹100 of revenue as net profit.
Cash quality
0.4×Cash from Zydus Lifesciences Limited's business was 0.4× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
15.9×Zydus Lifesciences Limited's operating profit covered its interest costs 15.9 times in the year to Mar 2026.
Cash vs debt
Net debtZydus Lifesciences Limited had ₹7,525 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Zydus Lifesciences Limited's P/E ratio?
Investors pay ₹25.2 for every ₹1 of Zydus Lifesciences Limited's yearly profit, lower than 72% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zydus Lifesciences Limited: ₹112,658 Cr ÷ ₹27,111 Cr (31 Mar 2026) = 4.2.
What is Zydus Lifesciences Limited's return on equity?
Zydus Lifesciences Limited earned 16.6% on its shareholders' money over the last year, higher than 64% of Healthcare companies in India.
How much does Zydus Lifesciences Limited owe compared with what it owns?
Zydus Lifesciences Limited owes ₹0.44 for every ₹1 it owns (low), higher than 67% of Healthcare companies in India.
Does Zydus Lifesciences Limited pay a dividend?
Yes. Zydus Lifesciences Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Is Zydus Lifesciences Limited's revenue growing?
Revenue rose 18% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.